Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
RNA 
Avidity Biosciences Inc (RNA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: RNA (5-star) is a STRONG-BUY. BUY since 63 days. Simulated Profits (42.54%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $74.64
1 Year Target Price $74.64
| 9 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 415.19% | Avg. Invested days 40 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.90B USD | Price to earnings Ratio - | 1Y Target Price 74.64 |
Price to earnings Ratio - | 1Y Target Price 74.64 | ||
Volume (30-day avg) 15 | Beta 0.96 | 52 Weeks Range 21.51 - 72.61 | Updated Date 01/8/2026 |
52 Weeks Range 21.51 - 72.61 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1513.47% |
Management Effectiveness
Return on Assets (TTM) -20.28% | Return on Equity (TTM) -32.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9078533448 | Price to Sales(TTM) 522.54 |
Enterprise Value 9078533448 | Price to Sales(TTM) 522.54 | ||
Enterprise Value to Revenue 435.05 | Enterprise Value to EBITDA -5.72 | Shares Outstanding 150675742 | Shares Floating 128515861 |
Shares Outstanding 150675742 | Shares Floating 128515861 | ||
Percent Insiders 4.14 | Percent Institutions 104.11 |
Upturn AI SWOT
Avidity Biosciences Inc
Company Overview
History and Background
Avidity Biosciences, Inc. was founded in 2012 with the goal of developing a new class of RNA therapeutics. The company's core innovation lies in its Antibody Oligonucleotide Conjugates (AOCs) platform, which aims to overcome the limitations of traditional RNA-based therapies by enabling tissue-specific delivery. A significant milestone was its Initial Public Offering (IPO) in 2021, which provided capital for further research and clinical development. Avidity has evolved from a preclinical-stage company to one with multiple programs in clinical trials, focusing on rare genetic diseases and other conditions where targeted RNA intervention could be transformative.
Core Business Areas
- RNA Therapeutics: Avidity Biosciences is focused on developing novel RNA therapeutics using its proprietary Antibody Oligonucleotide Conjugate (AOC) platform. This platform combines the specificity of antibodies with the potent gene-silencing ability of RNA interference (RNAi) to deliver RNA therapies to targeted tissues and cells. The goal is to improve efficacy and reduce off-target effects compared to non-conjugated RNA drugs.
Leadership and Structure
Avidity Biosciences is led by a management team with expertise in biotechnology, drug development, and corporate strategy. Specific leadership roles (CEO, CSO, CFO, etc.) and the overall organizational structure are typical of a publicly traded biotechnology company, with departments dedicated to research and development, clinical operations, regulatory affairs, manufacturing, and business development.
Top Products and Market Share
Key Offerings
- Description: AOC 1001 is an investigational RNA therapeutic designed to treat individuals with Duchenne muscular dystrophy (DMD) by increasing muscle production of utrophin. It utilizes Avidity's AOC platform for targeted delivery to skeletal, cardiac, and diaphragm muscles. Competitors in the DMD space include Sarepta Therapeutics, Pfizer, and other companies developing gene therapies and exon-skipping technologies.
- Market Share Data: Market share for this specific investigational therapy is not applicable as it is in clinical development. The overall DMD market is significant and growing, with various therapeutic modalities vying for dominance.
- Product Name 1: AOC 1001 (DRIVE-HRD)
- Description: AOC 1020 is an investigational RNA therapeutic being developed for the treatment of Wilson disease, a rare genetic disorder that causes copper to accumulate in the liver, brain, and other organs. It aims to reduce the production of a specific protein involved in copper metabolism. Competitors include existing chelating agents and emerging therapies for Wilson disease.
- Market Share Data: Market share for this investigational therapy is not applicable. The market for rare genetic diseases like Wilson disease is niche but can be substantial for effective treatments.
- Product Name 2: AOC 1020
- Description: AOC 1043 is an investigational RNA therapeutic for the treatment of rare diseases of the liver. It is designed for systemic delivery and aims to target specific hepatic pathways. Competitors will vary depending on the specific liver indication.
- Market Share Data: Market share for this investigational therapy is not applicable.
- Product Name 3: AOC 1043
Market Dynamics
Industry Overview
Avidity Biosciences operates within the rapidly evolving biotechnology and pharmaceutical industry, specifically focusing on the burgeoning field of RNA therapeutics. This sector is characterized by intense innovation, significant investment in research and development, and a growing pipeline of novel treatments for a wide range of diseases, including rare genetic disorders and chronic conditions. The industry is driven by advances in genomics, molecular biology, and drug delivery technologies, with a strong emphasis on precision medicine and targeted therapies.
Positioning
Avidity Biosciences is positioned as a pioneer in the development of Antibody Oligonucleotide Conjugates (AOCs), a novel class of RNA therapeutics. Its key competitive advantage lies in its proprietary AOC platform, which aims to overcome the delivery challenges that have historically limited the efficacy and broad application of RNA-based therapies. By enabling targeted delivery to specific tissues, Avidity seeks to enhance therapeutic potency and reduce potential side effects, differentiating itself from traditional RNAi companies and other gene therapy developers.
Total Addressable Market (TAM)
The total addressable market for Avidity Biosciences is substantial and multifaceted, encompassing rare genetic diseases, common chronic diseases, and potentially oncology. For example, the global market for rare diseases therapeutics is projected to reach hundreds of billions of dollars in the coming years. Avidity is positioned to address significant portions of this TAM by developing targeted RNA therapies for a variety of unmet medical needs, with its AOC platform offering a potential solution for diseases requiring precise cellular and tissue targeting.
Upturn SWOT Analysis
Strengths
- Proprietary Antibody Oligonucleotide Conjugate (AOC) platform technology.
- Potential for tissue-specific delivery of RNA therapies, overcoming a key industry challenge.
- Diversified pipeline with programs in multiple therapeutic areas and stages of development.
- Experienced management team with a strong track record in biotechnology.
- Significant intellectual property portfolio protecting its core technology.
Weaknesses
- Early-stage company with no approved products, leading to significant development and regulatory risk.
- Reliance on clinical trial success for product approval and revenue generation.
- High research and development costs associated with novel drug discovery.
- Potential manufacturing complexities and scalability challenges for AOCs.
- Need for continued significant funding to advance pipeline programs.
Opportunities
- Expansion of AOC platform to a wider range of diseases and therapeutic modalities.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Leveraging advances in artificial intelligence and machine learning for drug discovery and development.
- Addressing significant unmet medical needs in rare diseases and other therapeutic areas.
- Potential for platform expansion into different delivery mechanisms or RNA modalities.
Threats
- Failure of clinical trials, leading to program discontinuation and financial setbacks.
- Intense competition from other RNA therapy developers and gene therapy companies.
- Regulatory hurdles and delays in obtaining drug approvals.
- Changes in the healthcare landscape, reimbursement policies, and market access.
- Technological obsolescence or the emergence of superior competing technologies.
Competitors and Market Share
Key Competitors
- Sarepta Therapeutics (SRPT)
- Pfizer Inc. (PFE)
- Biogen Inc. (BIIB)
Competitive Landscape
Avidity Biosciences faces a competitive landscape populated by established pharmaceutical giants and specialized biotechnology firms. While Avidity's AOC platform offers a novel approach to RNA delivery, competitors like Sarepta Therapeutics and Pfizer have advanced pipelines and approved therapies for conditions like Duchenne muscular dystrophy. Avidity's advantage lies in its potential for differentiated efficacy and safety profiles due to targeted delivery. However, it must contend with the significant resources, established manufacturing capabilities, and existing market presence of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Avidity Biosciences has demonstrated growth in its research and development activities, expanding its pipeline and advancing multiple programs into clinical trials. The company's growth has also been marked by its successful transition to a publicly traded entity following its IPO. Its scientific advancements in the AOC platform represent a significant aspect of its historical growth.
Future Projections: Future growth projections for Avidity Biosciences are contingent upon the successful progression of its clinical pipeline. Analyst expectations typically focus on potential regulatory approvals and subsequent market penetration for its lead candidates, such as AOC 1001 for Duchenne muscular dystrophy. Success in these areas could lead to substantial revenue growth and increased market valuation.
Recent Initiatives: Recent initiatives at Avidity Biosciences have likely focused on advancing its lead clinical programs (e.g., AOC 1001 in the DRIVE-HRD study), expanding its pipeline through internal R&D and potential collaborations, and optimizing its AOC platform for broader therapeutic applications. The company also likely prioritizes building strategic partnerships and securing adequate funding to support its ongoing development efforts.
Summary
Avidity Biosciences is an early-stage biotechnology company with a promising proprietary platform for RNA therapeutics, aiming to overcome delivery challenges. Its core strength lies in its innovative AOC technology, which has the potential to unlock new treatment possibilities. However, the company faces significant risks inherent in drug development, including clinical trial failures and intense competition. Continued successful clinical progression and strategic partnerships will be crucial for its future growth and to realize its potential in addressing unmet medical needs.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (e.g., 10-K, 10-Q)
- Financial Data Providers (e.g., Bloomberg, Refinitiv)
- Industry Research Reports
- Company Press Releases and Website
Disclaimers:
This JSON output is generated based on publicly available information and should not be considered financial advice. Investment decisions should be made in consultation with a qualified financial advisor. Market share data is estimated and illustrative due to the early stage of many of Avidity's programs. Competitor and similar company lists are not exhaustive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avidity Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-06-28 | President, CEO & Director Ms. Sarah Boyce | ||
Sector Healthcare | Industry Biotechnology | Full time employees 391 | |
Full time employees 391 | |||
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.